Dubai’s Fakeeh University Hospital has established itself as a global hub for advanced gene therapy, achieving significant medical milestones that position the United Arab Emirates at the forefront of specialized healthcare innovation. The hospital has pioneered groundbreaking treatments for rare genetic and neuromuscular disorders, marking a transformative moment for regional medical capabilities.
In a landmark achievement for Middle Eastern healthcare, the facility became the first in the region to administer Duvyzat (givinostat), an advanced therapeutic agent for managing Duchenne muscular dystrophy (DMD). This devastating inherited neuromuscular condition predominantly affects male children, causing progressive muscle deterioration, mobility loss, and severe cardiorespiratory complications. Timely intervention with sophisticated treatments like Duvyzat proves crucial in decelerating disease advancement while enhancing both longevity and life quality for young patients.
Concurrently, the hospital has accomplished another world-class medical breakthrough by delivering among the earliest intrathecal gene therapies for spinal muscular atrophy (SMA), commercially known as ITVISMA. This severe genetic disorder involves the degeneration of motor neurons, leading to progressive muscular weakness, respiratory impairment, and complete loss of motor function. Gene-based interventions have revolutionized treatment outcomes for pediatric patients, especially when administered promptly within comprehensive, multidisciplinary clinical settings.
These medical advancements significantly bolster Dubai’s emerging reputation as a destination for world-class tertiary care, attracting international patients seeking cutting-edge treatments previously unavailable in the region. The hospital’s pioneering work not only addresses critical healthcare gaps for rare diseases but also demonstrates the UAE’s growing capacity to compete with leading Western medical institutions in specialized therapeutic domains.